In March 2022, a young biotech reported positive results from a drug trial. The microcap company, Longeveron, went on to rise +83% in the hours following the alert
In March 2022, a young biotech reported positive results from a drug trial. The low volume stock began rising on the announcement and LevelFields' AI caught the event shortly after the announcement was released.
The microcap company, Longeveron, went on to rise +83% in the hours following the alert. Over the next few days, the stock price pulled back. A month later, the price was up another 50% though below the high made in March.
LevelFields' AI is designed to catch positive catalysts like the clinical trial readout from Longeveron. Early stage companies showing promise creating new medicines have the potential to generate hundreds of millions, if not billions in new revenue should the drug be approved for use by the U.S. Food and Drug Administration. While many play these events as short trades, these early stage companies have incredible long-term potential, both as acquisitions from large drug companies and from bringing the drugs to market themselves.
It is difficult to monitor the hundreds of companies and thousands of their announcements. And most often these companies are too small to garner media attention until after the share prices move enough to get their attention. Often, the media simply reports the big stock price moves after the fact - the next day or after the market closes. But that does not provide a chance to get into the trade.
LevelFields is a machine-learning AI system designed to locate events and pair the events to a directory of events known to move share prices. It then provides an alert to users looking for short or longer term trade ideas for events proven to alter the share price.
Once on the LevelFields platform, users can browse events as easy as one browses flights. While browsing for positive and negative event catalysts, users can filter by company financials, sector, time, and industry to find the types of companies and catalysts that map to their investment style.
